Intellia Therapeutics Inc 2023 SR
The report details Intellia Therapeutics' ESG strategy and performance, focusing on its mission to develop curative CRISPR-based therapies. Key achievements include the initiation of Phase 3 clinical trials and dosing over 100 patients with investigational treatments. The company highlights its diverse workforce, with women comprising 54% of all employees and 53% of senior leadership positions. Environmental initiatives include energy-efficient building practices and waste reduction programs, while community efforts involved significant charitable donations and employee volunteering. The report also aligns with SASB standards and outlines a comprehensive cybersecurity framework.
Company: Intellia Therapeutics Inc
Sector: Professional & technical services
Country: United States
Year: 2023
Type: SR
Pages: 46
Back to company
Intellia Therapeutics Inc
Corporate Responsibility Report
The report details Intellia Therapeutics' ESG strategy and performance, focusing on its mission to develop curative CRISPR-based therapies. Key achievements include the initiation of Phase 3 clinical trials and dosing over 100 patients with investigational treatments. The company highlights its diverse workforce, with women comprising 54% of all employees and 53% of senior leadership positions. Environmental initiatives include energy-efficient building practices and waste reduction programs, while community efforts involved significant charitable donations and employee volunteering. The report also aligns with SASB standards and outlines a comprehensive cybersecurity framework.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
2023
Fiscal Year
2023
Published
Apr 1, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees